News
Dr Goldberg on Investigational Agents in EGFR-mutant NSCLC
Sarah Goldberg, MD, MPH, associate professor, internal medicine (medical oncology), associate director, Medical Oncology-Hematology Program, research director, Center for Thoracic Cancers, chief, Thoracic Oncology, Yale School of Medicine, discusses ongoing investigations with antibody-drug conjugates (ADCs) and bispecific antibodies in patients with non–small cell lung cancer (NSCLC) harboring EGFR mutations.
Source: OncLive